A Randomized Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation Versus Standard Peri-Operative Care in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer
Sponsor: BMS/Cedars-Sinai
Protocol Number: 2018-01-McArthur-IPI
Start Date: 1/28/2019
Active, projected trial end date 10/2024